Hydrophobin-Coated Noisomes as Drug Carriers in Lung Cancer Cells - A Review

Srishti Namdeo ¹, Chandrapratap Dhimar ²

Targeted nanoparticle delivery to Lung Cancer Cells, using hydrophobin-coated niosomes, addressing multidrug resistance, and enhancing treatment efficacy.

Abstract

Nanoparticles loaded with anti-cancer drugs are designed to selectively target Lung Cancer Cells (LCCs) by interacting with various receptors. Hydrophobin-coated niosomes, a type of carrier system, show lower cytotoxicity in vitro compared to existing anti-cancer drugs. The hydrophobin-coated formulation demonstrates higher cytotoxicity against cancer cells than control cells. Lung cancer can spread to distant organs, posing challenges such as multidrug resistance and recurrence. Traditional chemotherapies may face resistance due to genetic mutations. Convolutional Neural Network (CNN)-based automatic organ segmentation has been validated for radiation treatment planning in lung cancer patients. LCCs-CNN niosomes, similar to liposomes, offer enhanced cellular membrane permeability and high biocompatibility. This carrier system shields the drug molecule from breakdown and deactivation. Hydrophobin-coated niosomes outperform polyethylene glycol-coated ones in various aspects, including size distribution, entrapment efficiency, release profile, biocompatibility, and cancer prevention success.

Keywords: Lung cancer cells, Drugs, Patients, Convolutional Neural Network.

References

Alam, J., Alam, S., & Hossan, A. (2018, February). Multi-stage lung cancer detection and prediction using multi-class svm classifie. In 2018 International conference on computer, communication, chemical, material and electronic engineering (IC4ME2) (pp. 1-4). IEEE.

Aparajay, P., & Dev, A. (2022). Functionalized niosomes as a smart delivery device in cancer and fungal infection. European Journal of Pharmaceutical Sciences, 168, 106052.

Aparajay, P., & Dev, A. (2022). Functionalized niosomes as a smart delivery device in cancer and fungal infection. European Journal of Pharmaceutical Sciences, 168, 106052.

Bade, B. C., & Cruz, C. S. D. (2020). Lung cancer 2020: epidemiology, etiology, and prevention. Clinics in chest medicine, 41(1), 1-24.

Barani, M., Mirzaei, M., Torkzadeh-Mahani, M., Lohrasbi-Nejad, A., & Nematollahi, M. H. (2020). A new formulation of hydrophobin-coated niosome as a drug carrier to cancer cells. Materials Science and Engineering: C, 113, 110975.

Barani, M., Mirzaei, M., Torkzadeh-Mahani, M., Lohrasbi-Nejad, A., & Nematollahi, M. H. (2020). A new formulation of hydrophobin-coated niosome as a drug carrier to cancer cells. Materials Science and Engineering: C, 113, 110975.

Bashkeran, T., Harun, A., Ngo, T. X., Suda, K., Umakoshi, H., Watanabe, N., & Nadzir, M. M. (2023). Niosomes in cancer treatment: A focus on curcumin encapsulation. Heliyon.

Caicun, Z. H. O. U., Jie, W. A. N. G., Baocheng, W. A. N. G., Cheng, Y., Zhehai, W. A. N. G., Baohui, H. A. N., ... & Hongyun, Z. H. A. O. (2021). Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version). Chinese Journal of Lung Cancer, 24(4).

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., ... & Baselga, J. (2023). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer. Journal of clinical oncology, 41(6), 1162-1171.

Ge, X., Wei, M., He, S., & Yuan, W. E. (2019). Advances of non-ionic surfactant vesicles (niosomes) and their application in drug delivery. Pharmaceutics, 11(2), 55.

Gunter, N. V., Teh, S. S., Jantan, I., Cespedes-Acuna, C. L., & Mah, S. H. (2023). The mechanisms of action of prenylated xanthones against breast, colon, and lung cancers, and their potential application against drug resistance. Phytochemistry Reviews, 22(3), 467-503.

Hasan, G. M., Hassan, M. I., Sohal, S. S., Shamsi, A., & Alam, M. (2023). Therapeutic targeting of regulated signaling pathways of non-small cell lung carcinoma. ACS omega, 8(30), 26685-26698.

https://www.kaggle.com/datasets/tejasurya/cancer-data-india

Kobir, M. E., Ahmed, A., Roni, M. A. H., Chakma, U., Amin, M. R., Chandro, A., & Kumer, A. (2023). Anti-lung cancer drug discovery approaches by polysaccharides: an in silico study, quantum calculation and molecular dynamics study. Journal of Biomolecular Structure and Dynamics, 41(14), 6616-6632.

Kondapi, A. K. (2021). Surfactant-and Biosurfactant-Based Therapeutics: Structure, Properties, and Recent Developments in Drug Delivery and Therapeutic Applications. Biosurfactants for a Sustainable Future: Production and Applications in the Environment and Biomedicine, 373-395.

Li, M. C., Coumar, M. S., Lin, S. Y., Lin, Y. S., Huang, G. L., Chen, C. H., ... & Hsieh, H. P. (2023). Development of furanopyrimidine-based orally active third-generation EGFR inhibitors for the treatment of non-small cell lung cancer. Journal of Medicinal Chemistry, 66(4), 2566-2588.

Limongi, T., Susa, F., Marini, M., Allione, M., Torre, B., Pisano, R., & di Fabrizio, E. (2021). Lipid-based nanovesicular drug delivery systems. Nanomaterials, 11(12), 3391.

Lu, X., Zhu, T., Chen, C., & Liu, Y. (2014). Right or left: the role of nanoparticles in pulmonary diseases. International journal of molecular sciences, 15(10), 17577-17600.

Mansoori-Kermani, A., Khalighi, S., Akbarzadeh, I., Niavol, F. R., Motasadizadeh, H., Mahdieh, A., ... & Mostafavi, E. (2022). Engineered hyaluronic acid-decorated niosomal nanoparticles for controlled and targeted delivery of epirubicin to treat breast cancer. Materials Today Bio, 16, 100349.

Moghtaderi, M., Sedaghatnia, K., Bourbour, M., Fatemizadeh, M., Salehi Moghaddam, Z., Hejabi, F., ... & Farasati Far, B. (2022). Niosomes: a novel targeted drug delivery system for cancer. Medical Oncology, 39(12), 240.

Nanglia, P., Kumar, S., Mahajan, A. N., Singh, P., & Rathee, D. (2021). A hybrid algorithm for lung cancer classification using SVM and Neural Networks. ICT Express, 7(3), 335-341.

Saeidi, Z., Giti, R., Rostami, M., & Mohammadi, F. (2023). Nanotechnology-based drug delivery systems in the transdermal treatment of melanoma. Advanced Pharmaceutical Bulletin, 13(4), 646.

Sasikumar, S., Renjith, P. N., Ramesh, K., & Sankaran, K. S. (2020, October). Attention based recurrent neural network for lung cancer detection. In 2020 Fourth International Conference on I-SMAC (IoT in Social, Mobile, Analytics and Cloud)(I-SMAC) (pp. 720-724). IEEE.

Witika, B. A., Bassey, K. E., Demana, P. H., Siwe-Noundou, X., & Poka, M. S. (2022). Current advances in specialised niosomal drug delivery: Manufacture, characterization and drug delivery applications. International Journal of Molecular Sciences, 23(17), 9668.

Witika, B. A., Bassey, K. E., Demana, P. H., Siwe-Noundou, X., & Poka, M. S. (2022). Current advances in specialised niosomal drug delivery: Manufacture, characterization and drug delivery applications. International Journal of Molecular Sciences, 23(17), 9668.

Yasamineh, S., Yasamineh, P., Kalajahi, H. G., Gholizadeh, O., Yekanipour, Z., Afkhami, H., ... & Dadashpour, M. (2022). A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system. International journal of pharmaceutics, 624, 121878.